Moligand™,10mM in DMSO Moligand™ for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
LMT-28 is an orally active and the first synthetic IL-6 inhibitor that functions through direct binding to gp130. LMT-28 shows low toxicity and selectively inhibits IL-6-induced phosphorylation of STAT3 , JAK2 , and gp130
In Vitro
LMT-28 reduces IL-6-induced luciferase activity by ~90% at a concentration of 50 μM and exhibits an IC 50 value of 5.9 μM. LMT-28 (1-10 μM; 72 hours) inhibits IL-6-induced proliferation of the human erythroleukemic cell line TF-1. ?\nLMT-28 (1-100 μM; 1 hour) selectively inhibits IL-6-induced phosphorylation of STAT3, JAK2, and gp130. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: TF-1 cells (1 ng/mL IL-6-induced) Concentration: 1, 10, 100, 1000, 10000 nM Incubation Time: 72 hours Result: Markedly inhibited IL-6–induced TF-1 proliferation with an IC50 value of 7.5 μM. Western Blot AnalysisCell Line: HepG2 cells (treated with 10 ng/mL IL-6) Concentration: 1, 3, 10, 30, and 100 μM Incubation Time: 1 hour Result: Inhibits IL-6-induced phosphorylation of STAT3, JAK2, and gp130.
In Vivo
LMT-28 (0-0.5 mg/kg; p.o.; once daily for 15 days) alleviates CIA in mice . ?\nLMT-28 (0.25 or 1 mg/kg; p.o.) ameliorates the progression of pancreatitis in mice. LMT-28 binds directly and specifically to gp130, and thereby inhibits the interaction of gp130 with the IL-6/IL-6Rα complex . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Six-week-old male DBA/1J mice (collagen-induced arthritis mice, CIA) Dosage: 0-0.5 mg/kg Administration: Oral; once daily for 15 days Result: Markedly reduced the serum levels of cartilage oligomeric matrix protein (COMP) by 50%, serum amyloid P (SAP) by 55%, and anti-CII IgG by 62%.
IC50& Target:IL-6
| Isomeric SMILES | CCCCCC(=C)[C@H]([C@H](C)C(=O)N1[C@H](COC1=O)C(C)C)O |
|---|---|
| PubChem CID | 49846977 |
| Molecular Weight | 311.42 |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →Our grade selection guide covers purity, stabilizer status, and application suitability for all variants in our catalog.
View Moligand™ grade guide →
